卫太医品牌怎么样 申请店铺

我要投票 卫太医在医疗器械行业中的票数:580 更新时间:2026-01-23
卫太医是哪个国家的品牌?「卫太医」是 青岛华仁太医药业有限公司 旗下著名品牌。该品牌发源于山东省青岛市,由创始人高向荣在2005-10-31期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力卫太医品牌出海!将品牌入驻外推网,定制卫太医品牌推广信息,可以显著提高卫太医产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

卫太医怎么样

蒲元和胃胶囊,知名胃药品牌,以中药固体制剂为主优秀西药为辅,具备了溶液剂/片剂/胶囊剂等剂型以及中药提取为一体的多剂型发展的综合生产能力


青岛华仁太医药业有限公司,是由原北海舰队后勤部直属企业——青岛海燕药厂进行“军转民”改造和技术升级后建立的股份制企业。

青岛华仁太医药业坚持“仁者爱人、药惠天下”的经营理念,以促进我国健康产业发展为己任,以提高人们健康水平为目标,始终关注我国中医药事业的现代化、标准化和国际化进程。公司坚持内部培养和外部引进相结合的人才战略,打造了一支素质高、专业过硬、凝聚力强的营销团队,建立了覆盖全国十九个省、直辖市,六十多个地级市的营销服务网络,正逐步成长为国家健康产业中研发、生产、运营、服务的典范和榜样。

新的起点,新的跨越,以收购苏州滋露药业有限公司后组建苏州华仁太医药业为起点,华仁太医药业正在展开新一轮的扩张。未来的华仁太医药业公司,将通过并购、控股以及合作开发等方式,广泛吸收世界医药领域新研究成果,在大力拓展医院处方药的营销网络的同时,积极打造全国OTC药品营销网络。

同时,通过全国范围内的市场运营,实现企业的资本化、品牌化、国际化运营,致力发展成为品种多样化、技术前瞻性的上市医药企业,积极为社会和大众创造药品精品,为大众生命健康保驾护航。


Puyuan Hewei capsule, a well-known brand of stomach medicine, is supplemented by excellent western medicine with solid Chinese medicine as the main ingredient. It has a comprehensive production capacity of multiple dosage forms such as solution / tablet / capsule and extraction of Chinese medicine. Qingdao Huaren Taiyi Pharmaceutical Co., Ltd. is an enterprise directly under the logistics department of the former Beihai fleet, Qingdao Haiyan pharmaceutical factory, which has carried out the "military to civilian" transformation and technical upgrading After the establishment of joint-stock enterprises. Qingdao Huaren Taiyi Pharmaceutical Co., Ltd. adheres to the business philosophy of "benevolent people love others, medicine benefits the world", takes promoting the development of China's health industry as its own duty, takes improving people's health level as its goal, and always pays attention to the modernization, standardization and internationalization process of China's traditional Chinese medicine. The company adheres to the talent strategy of combination of internal training and external introduction, builds a marketing team with high quality, professional excellence and strong cohesion, establishes a marketing service network covering 19 provinces, municipalities directly under the central government and more than 60 prefecture level cities, and is gradually growing into a model and model of R & D, production, operation and service in the national health industry. A new starting point, a new leap forward, with the acquisition of Suzhou Zilu Pharmaceutical Co., Ltd. and the establishment of Suzhou Huaren Taiyi Pharmaceutical Co., Ltd. as the starting point, Huaren Taiyi pharmaceutical industry is expanding in a new round. In the future, Huaren Taiyi Pharmaceutical Co., Ltd. will widely absorb new research results in the world's pharmaceutical field through M & A, holding and cooperative development, and actively build a national OTC drug marketing network while vigorously expanding the marketing network of hospital prescription drugs. At the same time, through the nationwide market operation, realize the capitalization, branding and international operation of the enterprise, and strive to develop into a listed pharmaceutical enterprise with diversified varieties and forward-looking technology, actively create high-quality pharmaceutical products for the society and the public, and guarantee the health of the public.

本文链接: https://brand.waitui.com/3190aaa58.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

美股大型科技股盘前涨跌不一,Arm涨超2%

36氪获悉,美股大型科技股盘前涨跌不一,截至发稿,Arm涨超2%,英伟达涨超1%,谷歌涨0.1%,微软涨0.06%;特斯拉跌0.17%,奈飞跌0.11%,亚马逊跌0.07%,苹果跌0.03%。

44分钟前

热门中概股美股盘前涨跌互现,阿里巴巴跌超1%

36氪获悉,热门中概股美股盘前涨跌互现,截至发稿,阿里巴巴、京东跌超1%,小鹏汽车跌近1%,网易跌0.48%,蔚来跌0.21%;百度涨超1%,拼多多涨0.75%,理想汽车涨0.42%,B站涨0.09%。

44分钟前

晶升股份:拟购买为准智能100%股份,交易作价8.57亿元

36氪获悉,晶升股份公告,公司拟通过发行股份及支付现金的方式购买本尚科技等10名交易对方持有的为准智能100%股份,同时募集配套资金。为准智能100%股份的交易作价为8.57亿元。本次交易构成关联交易和重大资产重组,但不构成重组上市。交易完成后,为准智能将成为上市公司控股子公司。

44分钟前

天合光能:将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”

36氪获悉,天合光能公告,公司拟缩减“年产35GW直拉单晶项目”的募集资金投资金额,不再实施二期15GW项目,并将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”。新项目预计2026年底建成并投入运营。公司表示,本次变更有利于提高募集资金使用效率,合理优化资源配置,巩固市场地位,不会对公司正常经营产生不利影响。该事项尚需提交公司股东会和债券持有人会议审议通过后方可实施。

44分钟前

宝洁第二财季净销售额222亿美元,同比增长1%

当地时间1月22日,宝洁公司发布2026财年第二季度(2025年10-12月)财报。财报显示,第二财季净销售额为222亿美元,同比增长1%;摊薄后每股净收益为1.78美元,同比下降5%。该公司维持2026财年总销售额同比增长1%至5%的指引区间,将2026财年摊薄后每股净收益增长指引从原先的3%-9%调整至1%-6%。(界面)

44分钟前

本页详细列出关于卫太医的品牌信息,含品牌所属公司介绍,卫太医所处行业的品牌地位及优势。
咨询